IM (Intramuscular) Injections for Warfarin (Coumadin) Treated Patients

ClotCare: Blood Clots, Stroke, Heart Attack

Monday, December 30, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	What Should we do About IM (Intramuscular) Injections for Warfarin-Treated Patients? Henry I. Bussey, Pharm.D. March, 2009 IM Injections should be avoided when the INR is supra-therapeutic but I'm not aware of studies evaluating IM Injections in patients with therapeutic INRs. Also, in our anticoagulation clinic, we continue to administer IM injections in warfarin-treated patients if the INR is not above the target range. Various sources, however, indicate that flu vaccine, pneumovax, and other vaccinations can be administered subcutaneously with an adequate immune response. The CDC website (www.cdc.gov/FLU/about/qa/vaxadmin.htm), about half-way down the page, indicates that a dose of influenza vaccine given subcutaneously should be counted as an effective dose and not be re-administered. Also, the American Academy of Allergy and Immunology describe several studies in which subcutaneously administered immunizations were successful in inducing immunogenicity; and pneumovax is available for either intramuscular or subcutaneous (but not intradermal) injection (www.merck.com/product/usa/pi_circulars/ p/pneumovax_23/pneumovax_pi.pdf). If you have additional information or a different take on this issue, please feel free to submit your comments to Marie Walker at webmaster@clotcare.org.	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Monday, December 30, 2024